Fulcrum Therapeutics Inc. (FULC) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Fulcrum Therapeutics Inc.

    NASDAQ: FULC · Real-Time Price · USD
    7.32
    -0.34 (-4.44%)
    At close: Sep 08, 2025, 1:57 PM

    Fulcrum Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 80M 2.81M 6.34M 19.16M
    Cost of Revenue
    		 1.59M n/a 2.41M 2.52M
    Gross Profit
    		 78.41M 2.81M 3.93M 16.65M
    Operating Income
    		 -21.9M -110.66M -112.56M -81.05M
    Interest Income
    		 n/a n/a n/a 207K
    Pretax Income
    		 -9.72M -97.33M -109.87M -80.85M
    Net Income
    		 -9.72M -97.33M -105.62M -78.33M
    Selling & General & Admin
    		 36.45M 41.67M 41.69M 30.52M
    Research & Development
    		 63.39M 71.8M 76.78M 69.7M
    Other Expenses
    		 2.06M n/a 2.69M 207K
    Operating Expenses
    		 101.9M 113.47M 118.48M 100.22M
    Interest Expense
    		 n/a n/a n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 101.9M 113.47M 118.48M 100.22M
    Income Tax Expense
    		 n/a n/a -4.25M -2.52M
    Shares Outstanding (Basic)
    		 61.98M 61.31M 44.99M 35.36M
    Shares Outstanding (Diluted)
    		 61.98M 61.31M 44.99M 35.36M
    EPS (Basic)
    		 -0.17 -1.59 -2.35 -2.22
    EPS (Diluted)
    		 -0.17 -1.59 -2.35 -2.22
    EBITDA
    		 -18.24M -108.49M -109.72M -78.54M
    EBIT
    		 -19.83M -110.66M -112.13M -81.05M
    Depreciation & Amortization
    		 1.59M 2.17M 2.41M 2.52M

    Add to Watchlist